News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Motley Fool Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of opakalim. Opakalim, the lead candidate from Biohaven's Kv7 platform, โฆ
Biohaven Ltd. and Yale University have been awarded a combined $4 million judgment in a trade secret misappropriation and breach of contract lawsuit against Avilar Therapeutics, Inc. and RA Capital Management GP, LLC. The judgment follows a jury verdict which found that RA Capital โฆ
A U.S. District Court in Delaware has formalized a $4 million award to Biohaven Ltd. and Yale University, ruling that RA Capital Management GP, LLC and Avilar Therapeutics, Inc. willfully and maliciously misappropriated a trade secret related to Yale's "MODA" protein degradation platform. The โฆ
Biohaven (BHVN) reported improved Q2 2026 earnings, reducing its net loss to US$137.31 million. While the stock's price-to-book ratio of 171.2x suggests overvaluation compared to industry averages, a Discounted Cash Flow (DCF) model from Simply Wall St indicates the shares might be significantly undervalued โฆ
Biohaven Ltd. (BHVN) reported narrower net losses for Q2 and H1 2026, with a Q2 net loss of US$137.31 million and an H1 net loss of US$267.84 million, both improvements over the previous year. Despite the reduced losses, the company remains unprofitable, and its โฆ
This article provides financial information for Biohaven Ltd. (NYSE: BHVN), specifically focusing on its forward price-to-earnings ratio. The content appears to be a page from a financial data platform, displaying the company's ticker, exchange, and a placeholder for the "Price to earnings forward" value.
Biohaven Ltd. (NYSE:BHVN) has received a "Moderate Buy" consensus rating from seventeen research firms, with an average 12-month price target of $21.75. The company's shares opened at $13.59, and it recently reported a quarterly EPS of negative $0.91, missing the consensus estimate. Institutional investors โฆ
Quantinno Capital Management LP significantly increased its stake in Biohaven Ltd. (BHVN) by 190% in the first quarter, bringing its total to 121,554 shares. Several other institutional investors also expanded their positions, contributing to the high institutional ownership of 88.78%. Despite a reported quarterly โฆ
Biohaven (BHVN) is gaining attention after expanding its oncology collaboration with Regeneron Pharmaceuticals. Despite a recent slight easing in share price, the stock shows strong 90-day returns, contrasting with weaker long-term performance. A discounted cash flow (DCF) model by Simply Wall St suggests Biohaven โฆ
Biohaven Ltd. reported narrowing losses in Q2 2026, with a net loss of US$137.31 million, and appointed AI-focused investor John Yetimoglu to its Board. Despite these developments, the company still faces significant financial risk due to zero revenue, heavy ongoing losses, and a short โฆ
Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a clinical supply agreement with Regeneron to evaluate the combination of BHV-1530 and Regeneron's cemiplimab (Libtayo) in patients with solid tumors. โฆ
Woodline Partners LP has reported a beneficial ownership of 5.1% in Biohaven Ltd., amounting to 7,660,280 Common Shares. This ownership grants Woodline Partners sole voting and dispositive power over these shares, which are held through Woodline Master Fund LP and Woodline Spire Master Fund โฆ
Renaissance Technologies LLC has acquired a new position in Biohaven Ltd. (NYSE:BHVN), purchasing 160,952 shares valued at approximately $1.36 million. This move comes as institutional investors collectively own 88.78% of Biohaven, with several major funds significantly increasing their stakes. Despite missing quarterly EPS expectations, โฆ
Bank of America Securities has reiterated a Buy rating on Biohaven Ltd. (BHVN) with a price target of $11.00, despite the stock closing higher at $14.54. Analyst Dina Ramadane, who covers the Healthcare sector, has a 61.54% success rate on her recommendations. The broader โฆ
RBC Capital has raised its price target for Biohaven Pharma (NYSE:BHVN) to $23 from $22, maintaining an Outperform rating, following the company's second-quarter 2026 earnings report. The firm highlights potential opportunities in troriluzole and degrader data, estimating a more than $4 billion market by โฆ
Biohaven Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company, reported a net loss of $267.8 million for the first half of 2026, primarily due to $204.6 million in research and development expenses. The company maintains liquidity with $267.9 million in cash, cash equivalents, and marketable โฆ
Biohaven (NYSE:BHVN) announced its quarterly earnings, reporting a loss of $0.78 per share, which missed analysts' consensus estimates by $0.02. Following the announcement, shares of Biohaven dropped 0.5% to $14.58. Despite the earnings miss, analyst sentiment for Biohaven remains a "Moderate Buy" with an โฆ
The Manufacturers Life Insurance Company increased its stake in Biohaven Ltd. (NYSE:BHVN) by 52.5% in Q1, now owning 202,975 shares valued at $1.72 million. Other institutional investors also significantly increased their holdings, with hedge funds and institutional investors collectively owning 88.78% of the stock. โฆ
Biohaven Ltd. has filed its Q2 2026 financial report, revealing continued operating losses but also a reduction in research and development spending compared to the previous year. This report covers the three- and six-month periods ending June 30, 2026. The full details are available โฆ
First extracellular protein degraders in the clinic demonstrate rapid and robust pharmacodynamic effects and compelling safety in nearly 200 individuals dosed, Phase 3 trial underway Positive clinical biomarker and patient data presented from Biohaven's extracellular degrader platform demonstrated deep, rapid, selective lowering of disease-driving โฆ
Biohaven Pharmaceutical Holding Co Ltd is expected to report its second-quarter earnings, with analysts forecasting a narrower loss of 75 cents per share. Investors will be closely watching the company's cash burn rate and updates on its epilepsy drug candidate, opakalim, which has topline โฆ
This article analyzes Biohaven Ltd. (BHVN) stock, highlighting a potential shift where strong near-term sentiment might challenge persistent mid and long-term weakness. It identifies resistance testing and outlines three AI-generated trading strategiesโPosition, Momentum Breakout, and Risk Hedgingโwith specific entry, target, and stop-loss zones for โฆ
Biohaven Ltd. has announced the appointment of John Yetimoglu to its Board of Directors and as a member of the Nominating and Governance Committee, effective August 6, 2026. Mr. Yetimoglu, founder and CIO of Infinitum, brings expertise in semiconductors, videogaming, and AI application platforms. โฆ
Biohaven Ltd. (NYSE: BHVN) has appointed John Yetimoglu, founder and CIO of Infinitum and a board director at Groq, to its Board of Directors. Yetimoglu brings extensive experience in frontier AI and technology investing, which Biohaven anticipates will strengthen its strategic oversight as it โฆ
Search by ticker symbol or company name and select a result to open its chart.
Start typing to find a stock or ETF.
Choose one or more countries for market search, or include every covered market.
Currently searching United States